PubMed:32471903 / 1090-1336 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/32471903","sourcedb":"PubMed","sourceid":"32471903","source_url":"https://www.ncbi.nlm.nih.gov/pubmed/32471903","text":"Use of conventional disease-modifying antirheumatic drug (DMARD) alone or in combination with biologics/Janus Kinase inhibitors was not associated with hospitalisation (OR 1.23, 95% CI 0.70 to 2.17 and OR 0.74, 95% CI 0.37 to 1.46, respectively).","tracks":[{"project":"LitCovid-OGER-BB","denotations":[{"id":"T14","span":{"begin":38,"end":56},"obj":"CHEBI:35842"},{"id":"T15","span":{"begin":38,"end":56},"obj":"CHEBI:35842"},{"id":"T16","span":{"begin":117,"end":127},"obj":"CHEBI:66921"},{"id":"T17","span":{"begin":117,"end":127},"obj":"CHEBI:66921"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"attributes":[{"subj":"T14","pred":"source","obj":"LitCovid-OGER-BB"},{"subj":"T15","pred":"source","obj":"LitCovid-OGER-BB"},{"subj":"T16","pred":"source","obj":"LitCovid-OGER-BB"},{"subj":"T17","pred":"source","obj":"LitCovid-OGER-BB"}]},{"project":"Inflammaging","denotations":[{"id":"T13","span":{"begin":0,"end":246},"obj":"Sentence"},{"id":"T13","span":{"begin":0,"end":246},"obj":"Sentence"}],"attributes":[{"subj":"T13","pred":"source","obj":"Inflammaging"},{"subj":"T13","pred":"source","obj":"Inflammaging"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"LitCovid-OGER-BB","color":"#93ecd7","default":true},{"id":"Inflammaging","color":"#ecbd93"}]}]}}